At our institution, we are initiating a clinical trial for patients with metastatic or irresectable TNBC who undergo a baseline [89Zr]Zr-atezolizumab PET/CT and a tumor biopsy for PD-L1 IHC before starting with first-line systemic therapy. This evidence concerns the gene CD274 and neoplasm.